PubMed Health⌕ Search

Biomedical subjects

E Palummeri

Publications and source records attributed to E Palummeri.

50 records · Page 3Linked to original sources
PubMedDate not supplied

Does calcitonin modulate anterior pituitary hormone secretion?

In a group of 5 healthy subjects salmon CT (sCT) infusion was unable to induce significant variations on basal secretory levels of LH, FSH, PRL and TSH. In a second group of 5 normal subjects, GnRH and TRH tests were performed both during sCT and saline infusion; a clear inhibition of TSH-stimulated levels and of PRL area was documented, while gonadotropin secretion was not significantly affected by sCT infusion. These results suggest that CT effect might be attributed to a change in intracellular calcium of pituitary cells; however the different behavior between TRH-and GnRH-stimulated hormones might be due to a different hormonal release mechanism. Furthermore the widespread recognition of CT-like immunoreactivity in adenohypophysis and in portions of the central nervous system suggests that CT may be a neurotransmitter or paracrine regulator.

Calcitonin↗
PubMedDate not supplied

Short-term intravenous therapy with Neridronate in Paget's disease.

AIMS: To describe the effects of two consecutive intravenous infusions of aminohexane bisphosphonate (Neridronate) in patients with active Paget's disease of bone. METHODS: The study population included 83 patients, aged 41 to 85 years, randomized to 4 cumulative doses of Neridronate (25, 50, 100, 200 mg) given over 2 days, with a follow up of 180 days. The baseline serum alkaline phosphatase activity was at least 10% above the upper limit of the laboratory range. The response to treatment was assessed by changes in the serum total alkaline phosphatase (primary end point of the study), bone alkaline phosphatase and N-telopeptide urinary excretion. RESULTS: All Neridronate doses significantly suppressed the biochemical indices of disease activity. The nadir of total alkaline phosphatase levels ranged from -16 % to -57.5% of pretreatment values in the four groups, with a dose-response relationship that was apparent even between the two highest doses. The proportion of patients still maintaining a partial response (decreases in serum total alkaline phosphatase >25%) at the 6 month follow-up was also related to the dose: 98%, 67%, 57%, 21% in the patients given 200, 100, 50, 25 mg respectively. The proportion of responders in terms of bone alkaline phosphatase and N-telopeptide excretion changes was similar. Bone pain attributed to Paget's disease was significantly reduced. A typical acute phase reaction (fever and/or arthromyalgia) occurred in 16 out of 83 patients. CONCLUSIONS: We conclude that all of the Neridronate doses tested here were well tolerated and effective in decreasing, in a dose-related manner the bone turnover parameters of Paget's disease. The highest dose (200 mg) resulted in the normalization of the markers of disease activity in more than 60% of the patients.

Adult↗
PubMedDate not supplied

[Sequential calcitriol-calcitonin in the therapy of osteoporosis].

Different therapeutic regimens have been proposed by Authors in the treatment of involutional (and particularly postmenopausal) osteoporosis. Following the up to date concepts on bone remodelling, an ADFR (Activate, Depress, Free, Repeat) trial was performed in 20 females affected by involutional osteoporosis. They were treated with Calcitriol 2 mcg/d for 7 days, followed by a 21 days period of 100 U/d Salmon Calcitonin + 1 g/d Calcitonin, followed by a 2-month period of Calcium alone. The cycles were repeated for 1 year and the results of densitometric examinations (radial mineral content evaluated by single photon absorptiometer, and vertebral mineral content evaluated by dual photon absorptiometer) and of biochemical markers (Ca++, P, osteocalcin, alkaline phosphatase, hydroxyproline) controlled every 3 months, were compared with those obtained in a group of patients treated only with Salmon Calcitonin and in a group treated with Calcium for 1 year. After two therapeutical cycles radial bone mineral density significantly increased; vertebral bone density also increased but not significantly. The effects were more evident in comparison to calcitonin alone treatment. A significant reduction in serum osteocalcin was documented. At the end of the therapy no further improvement was registered. This suggests that some variations and adaptation of therapeutic strategy are needed to achieve a more important and substantial improvement of bone conditions.

Administration, Oral↗
PubMedDate not supplied

[Role of serum pepsinogen I values in primary duodenal ulcer in childhood].

Serum pepsinogen I (PGI) was measured by radioimmunoassay in the fasting state in three homogeneous family groups composed of parents and their children. Group 1, families, did not suffer from primary duodenal ulcer (PDU). Group 2, 10 families had at least one parent with PDU diagnosed endoscopically. Group 3, 6 families, had at least one child with PDU and one parent with PDU diagnosed endoscopically. The analysis of variance (ANOVA) of PGI in the examined children, showed a significant difference between the three groups (F = 22.83; p = 0.005). In all 3 groups the ANOVA of serum PGI of the fathers and the mothers were significantly different: fathers (F = 4.4; p = 0.241); mothers (F = 3.4; p = 0.05). A correlation was noted between PGI of the fathers and PGI of the children (r = 0.31; p = 0.05); but a more significant correlation was observed between PGI of the mothers and PGI of the children (r = 0.48; p = 0.001). In group 3, the correlation between PGI of the mothers and PGI of the children was striking (r = 0.89; p = 0.025). However, the PGI of the fathers and the PGI of the children were not different in this group (r = 0.27; p = n.s.). The multiple correlation between PGI of the children and PGI of both parents was significant (r2 = 0.316). In group 3, the correlation was very high between the mothers and the children (r2 = 0.81).

Adult↗